Compare Enbridge Inc (ENB) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs ResMed Inc. — how do they compare? Enbridge Inc trades at $46.6 (market cap $103.38B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: Enbridge Inc is far larger — about 3.2× ResMed Inc.'s market cap, and Enbridge Inc pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and ResMed Inc. for 51 Days on average.
| ENB | RMD | |
|---|---|---|
Market Cap | $103.38B | $31.89B |
Volume | 3,684,305 | 618,314 |
Sector | Energy | Health |
52-Week High | $58.04 | $277.88 |
52-Week Low | $45.23 | $182.82 |
Typical Hold Time | 91 Days | 51 Days |
Enterprise Value | $185.39B | $31.24B |
Dividend Yield | 6.02% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $46.465, up 1.25% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly EPS beats and a 6% dividend yield. Revenue grew to $65.19B in 2025, with net income of $7.49B, though profit margins have fluctuated. Analyst consensus is mixed with a $61.63 price target, while recent news highlights its stable cash flow and expansion into renewables.
The outlook balances a high yield and growth projects against interest rate sensitivity and debt levels near 49% of assets. Upside exists if execution on the $41B backlog drives earnings, but macroeconomic pressures and technical weakness pose near-term risks for shareholders.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
